Results 111 to 120 of about 2,751,693 (208)

Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate.

open access: yesPLoS ONE, 2013
Selective inhibition of BCR/ABL expression by RNA interference has been demonstrated as an effective strategy in CML treatment and a reversal to imatinib resistance.
Yajuan Li   +9 more
doaj   +1 more source

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

open access: yes, 2005
Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA. Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.
Antonescu, C. R.   +12 more
core   +1 more source

Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report

open access: yesPrecision Radiation Oncology, 2017
Chronic myeloid leukemia (CML) is a clonal malignant hematopoietic disorder that arises in a hematopoietic stem cell. Its characteristic cytogenetic abnormality is an abnormal chromosome 22 called the Philadelphia (Ph) chromosome.
Meng Xiao   +7 more
doaj   +1 more source

The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia

open access: yesМедицинский вестник Юга России, 2010
Imatinib mesylate is a potent and high selective inhibitor of Bcr-Abl tyrosine kinase, which is established now as the standard of Philadelphia chromosome positive (Ph) chronic myeloid leukemia (CML) treatment.
S. I. Kutsev   +8 more
doaj  

Treatment‐free remission in CML patients with prior TKI failure is not influenced by previous BCR::ABL1 kinase domain mutations

open access: yes
British Journal of Haematology, Volume 209, Issue 5, Page 2326-2330, November 2026.
Simone Claudiani   +6 more
wiley   +1 more source

Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms

open access: yes, 2018
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by the t(9; 22) and the related oncogene, BCR-ABL. Tyrosine kinase activity of fusion protein BCR-ABL is the main cause of CML.
Yalda Hekmatshoar   +6 more
core   +1 more source

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia

open access: yes, 2012
Yusuf Baran,1 Guray Saydam21Department of Molecular Biology and Genetics, Izmir Institute of Technology, Izmir, Turkey; 2Department of Hematology, School of Medicine, Ege University, Izmir, TurkeyAbstract: Chronic myeloid leukemia (CML) is a malignant ...
Saydam G, Baran Y
core  

Additional file 10: of Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance

open access: yes, 2018
Figure S4. (A)The potential signaling pathway contributed to imatinib resistance in GIST. The green boxes and the solid arrows represented the previously reported signaling pathways related with imatinib resistance; the orange boxes and the dotted arrows
Tong Zhang (103827)   +13 more
core   +1 more source

Molecular mechanisms of imatinib resistance in gastrointestinal stromal tumor with focus on microRNAs [Elektronisk resurs]

open access: yes, 2014
Gastrointestinal stromal tumor (GIST) is mainly initialized by mutations in receptor tyrosine kinase genes KIT or PDGFRA. The development of imatinib, a small molecule inhibitor that targets these tyrosine kinase receptors, remarkably improved patient ...
Akçakaya, P,
core  

Home - About - Disclaimer - Privacy